CTT Pharma Adds Independent Director With NIH/NSF Experience
CTT Pharmaceuticals Holdings (OTC PINK:CTTH) has appointed Dr. Katherine Cole as an Independent Director. Dr. Cole brings extensive experience in biomedical research and academic leadership, including a Ph.D. in Pathology from the University of Maryland School of Medicine and three years at the National Cancer Institute (NIH) studying anti-cancer mechanisms.
Dr. Cole's credentials include positions as a biomedical scientist, professor, and vice Provost and Dean across four universities. She has authored twenty-two peer-reviewed papers and holds two patents related to a human liver cell line. Her research has been supported by grants from the National Science Foundation and the Howard Hughes Medical Institute.
CTT Pharmaceuticals Holdings (OTC PINK:CTTH) ha nominato la Dott.ssa Katherine Cole come Direttore Indipendente. La Dott.ssa Cole porta con sé una vasta esperienza nella ricerca biomedica e nella leadership accademica, incluso un dottorato in Patologia presso la Scuola di Medicina dell'Università del Maryland e tre anni trascorsi presso il National Cancer Institute (NIH) a studiare i meccanismi anti-cancro.
Le credenziali della Dott.ssa Cole includono ruoli come scienziata biomedica, professoressa e vice rettore e Dean in quattro università. Ha pubblicato ventidue articoli peer-reviewed e detiene due brevetti relativi a una linea cellulare epatica umana. La sua ricerca è stata sostenuta da finanziamenti della National Science Foundation e dell'Howard Hughes Medical Institute.
CTT Pharmaceuticals Holdings (OTC PINK:CTTH) ha nombrado a la Dra. Katherine Cole como Directora Independiente. La Dra. Cole aporta una amplia experiencia en investigación biomédica y liderazgo académico, incluyendo un doctorado en Patología de la Facultad de Medicina de la Universidad de Maryland y tres años en el National Cancer Institute (NIH) estudiando los mecanismos contra el cáncer.
Las credenciales de la Dra. Cole incluyen puestos como científica biomédica, profesora y vicerrectora y decana en cuatro universidades. Ha escrito veintidós artículos revisados por pares y posee dos patentes relacionadas con una línea de células hepáticas humanas. Su investigación ha sido apoyada por subvenciones de la National Science Foundation y del Howard Hughes Medical Institute.
CTT Pharmaceuticals Holdings (OTC PINK:CTTH)는 Katherine Cole 박사를 독립 이사로 임명했습니다. Cole 박사는 메릴랜드 대학교 의과대학에서 병리학 박사 학위를 보유하고 있으며, NIH 국립 암 연구소에서 3년 동안 항암 메커니즘에 대해 연구한 풍부한 생물 의학 연구 및 학문적 리더십 경험을 제공합니다.
Cole 박사의 자격은 생물 의학 과학자, 교수 및 네 개의 대학교에서 부총장 및 학장으로서의 직위를 포함합니다. 그녀는 22개의 동료 심사 논문을 저술하였으며, 인간 간 세포주와 관련된 두 개의 특허를 보유하고 있습니다. 그녀의 연구는 National Science Foundation과 Howard Hughes Medical Institute의 지원을 받았습니다.
CTT Pharmaceuticals Holdings (OTC PINK:CTTH) a nommé la Dr. Katherine Cole en tant que Directrice Indépendante. La Dr. Cole possède une vaste expérience en recherche biomédicale et en leadership académique, y compris un doctorat en pathologie de la Faculté de Médecine de l'Université du Maryland et trois ans passés au National Cancer Institute (NIH) à étudier les mécanismes anticancéreux.
Les qualifications de la Dr. Cole comprennent des postes en tant que scientifique biomédicale, professeure, ainsi que vice-rectrice et doyenne dans quatre universités. Elle a rédigé vingt-deux articles examinés par des pairs et détient deux brevets liés à une lignée de cellules hépatiques humaines. Sa recherche a été soutenue par des subventions de la National Science Foundation et du Howard Hughes Medical Institute.
CTT Pharmaceuticals Holdings (OTC PINK:CTTH) hat Dr. Katherine Cole zur unabhängigen Direktorin ernannt. Dr. Cole bringt umfassende Erfahrungen in der biomedizinischen Forschung und akademischen Führung mit, darunter einen Doktortitel in Pathologie von der medizinischen Fakultät der Universität Maryland und drei Jahre am National Cancer Institute (NIH), wo sie antikanzerogene Mechanismen studiert hat.
Die Qualifikationen von Dr. Cole umfassen Positionen als biomedizinische Wissenschaftlerin, Professorin sowie als stellvertretende Provost und Dekanin an vier Universitäten. Sie hat zweiundzwanzig fachbegutachtete Arbeiten verfasst und hält zwei Patente in Zusammenhang mit einer menschlichen Leberzelllinie. Ihre Forschung wurde durch Fördermittel der National Science Foundation und des Howard Hughes Medical Institute unterstützt.
- Addition of highly qualified director with extensive research background
- Director brings NIH/NCI research experience in cancer therapeutics
- Director holds two patents related to human liver cell line
- Track record of securing NSF and Howard Hughes Medical Institute grants
- None.
TAMPA, FL / ACCESS Newswire / February 5, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC PINK:CTTH) is pleased to announce adding Dr. Katherine Cole as an Independent Director for CTT. Dr. Cole. a Ph.D. in Pathology from the University of Maryland School of Medicine. Following her Ph.D. she spent 3 years at the National Cancer Institute(NCI) at the National Institutes of Health(NIH) where she spent her time focused on anti-cancer mechanisms of novel chemotherapeutic compounds. From there Dr. Cole worked at four different universities as a Biomedical scientist, professor, and eventually as a vice Provost and Dean. She has published twenty-two peer reviewed papers and has been granted two patents related to a human liver cell line. Dr. Cole has been awarded many notable grants including grants from the National Science Foundation(NSF) and the Howard Hughes Medical Institute. Dr. Cole's professional development as a scientist, an educator and a university-level administrator has provided her with a distinct scientific perspective and an ability to critically analyze meaningful data and research design. Her Ph.D. in Pathology from the University of Maryland School of Medicine and postdoctoral experience at the NIH/NCI in cancer research have positioned her well to not only understand the science behind this technology, but the impact from a human pathological perspective. CTT is honored to have Dr. Cole on our team and looks forward to her contributions.
About CTT Pharmaceuticals Holdings, Inc.
CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.
Investor Relations - 813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
Who is the new Independent Director appointed to CTT Pharmaceuticals (CTTH)?
What is Dr. Katherine Cole's research background at the National Institutes of Health?
How many peer-reviewed papers has CTTH's new director published?
What major grants has CTTH's new Independent Director received?
